IVBIY (Innovent Biologics) Other Stockholders Equity : $144 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Other Stockholders Equity?

Innovent Biologics's Other Stockholders Equity for the quarter that ended in Jun. 2024 was $144 Mil.

Innovent Biologics's quarterly Other Stockholders Equity increased from Jun. 2023 ($106 Mil) to Dec. 2023 ($136 Mil) and increased from Dec. 2023 ($136 Mil) to Jun. 2024 ($144 Mil).

Innovent Biologics's annual Other Stockholders Equity declined from Dec. 2021 ($1,622 Mil) to Dec. 2022 ($110 Mil) but then increased from Dec. 2022 ($110 Mil) to Dec. 2023 ($136 Mil).

Innovent Biologics Other Stockholders Equity Historical Data

The historical data trend for Innovent Biologics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Other Stockholders Equity Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Get a 7-Day Free Trial

1,342.60

1,621.89

109.57

135.93

1,801.70

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial												109.57	106.37	135.93	143.68	1,801.70

Innovent Biologics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Innovent Biologics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBIY) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IVBXF:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.